These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2435453)
21. Enzymology and subcellular localization of aldehyde oxidation in rat liver. Oxidation of 3,4-dihydroxyphenylacetaldehyde derived from dopamine to 3,4-dihydroxyphenylacetic acid. Tank AW; Weiner H; Thurman JA Biochem Pharmacol; 1981 Dec; 30(24):3265-75. PubMed ID: 7034733 [No Abstract] [Full Text] [Related]
22. Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. Anderson DG; Mariappan SV; Buettner GR; Doorn JA J Biol Chem; 2011 Jul; 286(30):26978-86. PubMed ID: 21642436 [TBL] [Abstract][Full Text] [Related]
23. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Burke WJ; Li SW; Williams EA; Nonneman R; Zahm DS Brain Res; 2003 Nov; 989(2):205-13. PubMed ID: 14556942 [TBL] [Abstract][Full Text] [Related]
25. Determination of monoamine oxidase B activity by high-performance liquid chromatography with electrochemical detection. Husseini H; Mitrovic V; Schlepper M J Chromatogr B Biomed Appl; 1995 Oct; 672(1):138-42. PubMed ID: 8590926 [TBL] [Abstract][Full Text] [Related]
26. Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones. Legros H; Janin F; Dourmap N; Bonnet JJ; Costentin J J Neurosci Res; 2004 Feb; 75(3):429-35. PubMed ID: 14743456 [TBL] [Abstract][Full Text] [Related]
27. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease. Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103 [TBL] [Abstract][Full Text] [Related]
28. Simultaneous determination of carbidopa, levodopa and 3,4-dihydroxyphenyl-acetic acid using high-performance liquid chromatography with electrochemical detection. Nissinen E; Taskinen J J Chromatogr; 1982 Sep; 231(2):459-62. PubMed ID: 7130324 [No Abstract] [Full Text] [Related]
29. Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde. Holmes C; Whittaker N; Heredia-Moya J; Goldstein DS Clin Chem; 2010 May; 56(5):832-8. PubMed ID: 20207766 [TBL] [Abstract][Full Text] [Related]
30. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde. Vanle BC; Florang VR; Murry DJ; Aguirre AL; Doorn JA Biochem Biophys Res Commun; 2017 Oct; 492(2):275-281. PubMed ID: 28830811 [TBL] [Abstract][Full Text] [Related]
31. Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography. Burke WJ; Chung HD; Li SW Anal Biochem; 1999 Aug; 273(1):111-6. PubMed ID: 10452806 [TBL] [Abstract][Full Text] [Related]
32. In vitro inhibition of glutathione-S-transferase by dopamine and its metabolites, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid. Crawford RA; Bowman KR; Cagle BS; Doorn JA Neurotoxicology; 2021 Sep; 86():85-93. PubMed ID: 34314733 [TBL] [Abstract][Full Text] [Related]
33. Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite. Anderson DG; Florang VR; Schamp JH; Buettner GR; Doorn JA Chem Res Toxicol; 2016 Jul; 29(7):1098-107. PubMed ID: 27268734 [TBL] [Abstract][Full Text] [Related]
34. Neurochemical evidence that cocaine- and amphetamine-regulated transcript (CART) 55-102 peptide modulates the dopaminergic reward system by decreasing the dopamine release in the mouse nucleus accumbens. Rakovska A; Baranyi M; Windisch K; Petkova-Kirova P; Gagov H; Kalfin R Brain Res Bull; 2017 Sep; 134():246-252. PubMed ID: 28802898 [TBL] [Abstract][Full Text] [Related]
37. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde. Lima VA; do Nascimento LA; Eliezer D; Follmer C ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158 [TBL] [Abstract][Full Text] [Related]
38. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. Rees JN; Florang VR; Anderson DG; Doorn JA Chem Res Toxicol; 2007 Oct; 20(10):1536-42. PubMed ID: 17887726 [TBL] [Abstract][Full Text] [Related]
39. Catechols in post-mortem brain of patients with Parkinson disease. Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Basile MJ; Mash DC Eur J Neurol; 2011 May; 18(5):703-10. PubMed ID: 21073636 [TBL] [Abstract][Full Text] [Related]
40. Reduction of dihydroxyphenylacetic acid by a novel enzyme in the rat brain. Xu CL; Sim MK Biochem Pharmacol; 1995 Oct; 50(9):1333-7. PubMed ID: 7503780 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]